These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 39069074)
1. ST3GAL1 Promotes Malignant Phenotypes in Intrahepatic Cholangiocarcinoma. Chen F; Gao K; Li Y; Li Y; Wu Y; Dong L; Yang Z; Shi J; Guo K; Gao Q; Lu H; Zhang S Mol Cell Proteomics; 2024 Sep; 23(9):100821. PubMed ID: 39069074 [TBL] [Abstract][Full Text] [Related]
2. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357 [TBL] [Abstract][Full Text] [Related]
3. Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD. Yang L; Niu K; Wang J; Shen W; Jiang R; Liu L; Song W; Wang X; Zhang X; Zhang R; Wei D; Fan M; Jia L; Tao K J Hepatol; 2024 Oct; 81(4):651-666. PubMed ID: 38679071 [TBL] [Abstract][Full Text] [Related]
4. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer. Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371 [TBL] [Abstract][Full Text] [Related]
5. FUT8 is regulated by miR-122-5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling. Chen F; Li Y; Aye L; Wu Y; Dong L; Yang Z; Gao Q; Zhang S Cell Oncol (Dordr); 2023 Feb; 46(1):79-91. PubMed ID: 36348252 [TBL] [Abstract][Full Text] [Related]
6. miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma. Lixin S; Wei S; Haibin S; Qingfu L; Tiemin P Mol Carcinog; 2020 Dec; 59(12):1371-1381. PubMed ID: 33052627 [TBL] [Abstract][Full Text] [Related]
7. Human B Cell Differentiation Is Characterized by Progressive Remodeling of O-Linked Glycans. Giovannone N; Antonopoulos A; Liang J; Geddes Sweeney J; Kudelka MR; King SL; Lee GS; Cummings RD; Dell A; Barthel SR; Widlund HR; Haslam SM; Dimitroff CJ Front Immunol; 2018; 9():2857. PubMed ID: 30619255 [TBL] [Abstract][Full Text] [Related]
8. Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes. Chen Z; Gao J; Li Z; Ma D; Wang Y; Cheng Q; Zhu J; Li Z Liver Int; 2024 Sep; 44(9):2477-2493. PubMed ID: 38924592 [TBL] [Abstract][Full Text] [Related]
9. Unveiling the role of HP1α-HDAC1-STAT1 axis as a therapeutic target for HP1α-positive intrahepatic cholangiocarcinoma. Xiong F; Wang D; Xiong W; Wang X; Huang WH; Wu GH; Liu WZ; Wang Q; Chen JS; Kuai YY; Wang B; Chen YJ J Exp Clin Cancer Res; 2024 May; 43(1):152. PubMed ID: 38812060 [TBL] [Abstract][Full Text] [Related]
10. SSH1 promotes progression of intrahepatic cholangiocarcinoma via p38 MAPK-CXCL8 axis. Chen F; Aye L; Yu L; Liu L; Liu Y; Lin Y; Gao D; Gao Q; Zhang S Carcinogenesis; 2023 May; 44(3):232-241. PubMed ID: 36857607 [TBL] [Abstract][Full Text] [Related]
11. Membrane RRM2-positive cells represent a malignant population with cancer stem cell features in intrahepatic cholangiocarcinoma. Zhao Y; Xue S; Wei D; Zhang J; Zhang N; Mao L; Liu N; Zhao L; Yan J; Wang Y; Cai X; Zhu S; Roessler S; Ji J J Exp Clin Cancer Res; 2024 Sep; 43(1):255. PubMed ID: 39243109 [TBL] [Abstract][Full Text] [Related]
12. Aberrant fucosylation sustains the NOTCH and EGFR/NF-κB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma. Ament CE; Steinmann S; Evert K; Pes GM; Ribback S; Gigante I; Pizzuto E; Banales JM; Rodrigues PM; Olaizola P; Wang H; Giannelli G; Chen X; Evert M; Calvisi DF Hepatology; 2023 Dec; 78(6):1742-1754. PubMed ID: 36789652 [TBL] [Abstract][Full Text] [Related]
13. Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge. Carotti S; Zingariello M; Francesconi M; D'Andrea L; Latasa MU; Colyn L; Fernandez-Barrena MG; Flammia RS; Falchi M; Righi D; Pedini G; Pantano F; Bagni C; Perrone G; Rana RA; Avila MA; Morini S; Zalfa F Oncogene; 2021 Jun; 40(23):4033-4049. PubMed ID: 34017076 [TBL] [Abstract][Full Text] [Related]
14. Sialylation of CD55 by ST3GAL1 Facilitates Immune Evasion in Cancer. Lin WD; Fan TC; Hung JT; Yeo HL; Wang SH; Kuo CW; Khoo KH; Pai LM; Yu J; Yu AL Cancer Immunol Res; 2021 Jan; 9(1):113-122. PubMed ID: 33177111 [TBL] [Abstract][Full Text] [Related]
15. Digitoxin inhibits ICC cell properties via the NF‑κB/ST6GAL1 signaling pathway. Zhan Y; Wang R; Huang C; Xu X; Xiao X; Wu L; Wei J; Long T; Gao C Oncol Rep; 2024 Aug; 52(2):. PubMed ID: 38940341 [TBL] [Abstract][Full Text] [Related]
16. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs. Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317 [No Abstract] [Full Text] [Related]
17. ADAR1 promotes cisplatin resistance in intrahepatic cholangiocarcinoma by regulating BRCA2 expression through A-to-I editing manner. Liu Q; Huang CS; Chen S; Zhu YQ; Huang XT; Zhao GY; Xu QC; Shi YH; Li W; Wang R; Yin XY Cell Prolif; 2024 Oct; 57(10):e13659. PubMed ID: 38773866 [TBL] [Abstract][Full Text] [Related]
18. ST3GAL1-Associated Transcriptomic Program in Glioblastoma Tumor Growth, Invasion, and Prognosis. Chong YK; Sandanaraj E; Koh LW; Thangaveloo M; Tan MS; Koh GR; Toh TB; Lim GG; Holbrook JD; Kon OL; Nadarajah M; Ng I; Ng WH; Tan NS; Lim KL; Tang C; Ang BT J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26547933 [TBL] [Abstract][Full Text] [Related]
19. Oncogenic Roles of Laminin Subunit Gamma-2 in Intrahepatic Cholangiocarcinoma via Promoting EGFR Translation. Zhang J; Ji F; Tan Y; Zhao L; Zhao Y; Liu J; Shao L; Shi J; Ye M; He X; Jin J; Zhao B; Huang J; Roessler S; Zheng X; Ji J Adv Sci (Weinh); 2024 Jun; 11(21):e2309010. PubMed ID: 38526177 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma. Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]